Use of B-cell biomarkers can help reduce rituximab dosing for patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) without compromising efficacy, neurologists in NSW have shown. Presenting their findings at PACTRIMS 2018 in Sydney, Dr Benjamin Trewin and colleagues at the RPAH Neuroimmunology Clinic noted that rituximab has become the standard of care in NMOSD following ...
Sydney clinic pioneers precision therapy for NMOSD patients
By Michael Woodhead
2 Nov 2018